Physician
Associated Retinal Surgeons, PA
Associated Retinal Surgeons, PA was paid $2.58M by Medicaid between Jan 2018 and Nov 2024, across 12 billing codes. Its largest line is J0178, Injection, aflibercept, 1 mg — 29% of everything it billed.
33Billing provider infoASSOCIATED RETINAL SURGEONS, PA
CHERRY HILL, NJ 08034
CHERRY HILL, NJ 08034
33aNPI1679625172assigned 01/17/2007
33bProvider typeRetina Specialist (Ophthalmology) Physician
28Total paid$2.58M
24GClaims36,620
24DCodes billed12
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Retina Specialist (Ophthalmology) Physician providers in New Jersey
Rank by total paid#1 of 5
Median peer was paid$84K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,848 | $340K | |
| 2019 | 6,016 | $298K | |
| 2020 | 3,249 | $165K | |
| 2021 | 5,269 | $280K | |
| 2022 | 5,528 | $318K | |
| 2023 | 5,878 | $704K | |
| 2024incomplete | 3,832 | $475K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 29% | 664 | 511 | $753K |
| 67028 | Intravitreal injection of a pharmacologic agent | 27% | 9,010 | 8,299 | $706K |
| 92134 | 24% | 20,347 | 18,881 | $609K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 3,441 | 3,356 | $331K |
| J9035 | Injection, bevacizumab, 10 mg | 2.9% | 739 | 721 | $74K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1.3% | 87 | 87 | $34K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.1% | 391 | 386 | $28K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,119 | 1,079 | $17K |
| 92201 | <1% | 757 | 719 | $14K | |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 13 | 12 | $10K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 39 | 39 | $4K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 13 | 13 | $372.49 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHEPPARD, COURTNEY (CAO/CFO)
| Provider | Location | Paid |
|---|---|---|
| Retinovitreous Associates LTD | Plymouth Meeting, PA | $5.10M |
| Retinovitreous Associates LTD | Wilmington, DE | $508K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.